Search research articles
Contact Us
Filters
Showing results (1-10 of 54) with videos related to
Page
of 6
Sort By:
Pharmaceutical Research
|
July 11, 2009
Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression
Jianping Zhang, Javier G Blanco
Journal of Pediatric Hematology/Oncology
|
February 25, 2016
Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia
Erik Hefti, Javier G Blanco
Pharmacotherapy
|
December 9, 2016
Pharmacotherapeutic Considerations for Individuals with Down Syndrome
Erik Hefti, Javier G Blanco
Journal of AHIMA
|
April 9, 2016
Documenting Pharmacogenomic Testing with CPT Codes
Erik Hefti, Javier G Blanco
Cardiovascular Toxicology
|
January 25, 2015
Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review
Erik Hefti, Javier G Blanco
Pharmaceutical Research
|
January 6, 2018
Regulation of the Human Fc-Neonatal Receptor alpha-Chain Gene FCGRT by MicroRNA-3181
Daniel C Ferguson, Javier G Blanco
Experimental and Molecular Pathology
|
June 16, 2019
Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome
Adolfo Quiñones-Lombraña, Javier G Blanco
Biochimica Et Biophysica Acta
|
April 15, 2015
Chromosome 21-derived hsa-miR-155-5p regulates mitochondrial biogenesis by targeting Mitochondrial Transcription Factor A (TFAM)
Adolfo Quiñones-Lombraña, Javier G Blanco
Human Mutation
|
September 6, 2016
Analysis of Heteroplasmic Variants in the Cardiac Mitochondrial Genome of Individuals with Down Syndrome
Erik Hefti, Jonathan Bard, Javier G Blanco
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 13, 2004
Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3)
Sukhwinder S Lakhman, Debashis Ghosh, Javier G Blanco
Page
of 6
Search research articles
Search
Showing results (1-10 of 54) with videos related to
Sort By:
Page
of 6
Pharmaceutical Research
|
July 11, 2009
Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression
Jianping Zhang, Javier G Blanco
Journal of Pediatric Hematology/Oncology
|
February 25, 2016
Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia
Erik Hefti, Javier G Blanco
Pharmacotherapy
|
December 9, 2016
Pharmacotherapeutic Considerations for Individuals with Down Syndrome
Erik Hefti, Javier G Blanco
Journal of AHIMA
|
April 9, 2016
Documenting Pharmacogenomic Testing with CPT Codes
Erik Hefti, Javier G Blanco
Cardiovascular Toxicology
|
January 25, 2015
Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review
Erik Hefti, Javier G Blanco
Pharmaceutical Research
|
January 6, 2018
Regulation of the Human Fc-Neonatal Receptor alpha-Chain Gene FCGRT by MicroRNA-3181
Daniel C Ferguson, Javier G Blanco
Experimental and Molecular Pathology
|
June 16, 2019
Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome
Adolfo Quiñones-Lombraña, Javier G Blanco
Biochimica Et Biophysica Acta
|
April 15, 2015
Chromosome 21-derived hsa-miR-155-5p regulates mitochondrial biogenesis by targeting Mitochondrial Transcription Factor A (TFAM)
Adolfo Quiñones-Lombraña, Javier G Blanco
Human Mutation
|
September 6, 2016
Analysis of Heteroplasmic Variants in the Cardiac Mitochondrial Genome of Individuals with Down Syndrome
Erik Hefti, Jonathan Bard, Javier G Blanco
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 13, 2004
Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3)
Sukhwinder S Lakhman, Debashis Ghosh, Javier G Blanco
Page
of 6